Bayer Pharmaceutical Press Release: Nexavar Approved for Medullary Thyroid Cancer in Japan
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- March 2, 2016
- 1 min read
On February 29, Bayer Pharmaceutical received regulatory approval in Japan for Nexavar (sorafenib) for the treatment of medullary thyroid cancer. Approximately 29,000 thyroid cancer patients exist in Japan, of whom approximately 5% have medullary thyroid cancer.
Nexavar targets multiple kinases including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-B. It had previously received approval in Japan for renal cell carcinoma in January 2008 and for unresectable hepatocellular carcinoma in May 2009. This latest approval for medullary thyroid cancer further broadens the indications for this multikinase inhibitor.
For the full press release, please refer to the following link: http://byl.bayer.co.jp/html/press_release/2016/news2016-02-29.pdf
Thyroid Cancer
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4